Company Overview
Maze Therapeutics, Inc. operates as a clinical stage biopharmaceutical company dedicated to developing small molecule precision medicines designed to treat renal, cardiovascular, related metabolic diseases, and obesity within the United States. The firm functions within the healthcare sector and specifically the biotechnology industry, an environment characterized by high research and development expenditures and reliance on successful product approvals to generate future cash flows. As of the latest data, the company carries a market capitalization of $2.31B and employs 125 individuals to advance its clinical pipeline. While the company reports an annual revenue figure listed as N/A, indicating it is likely pre-commercial or deriving minimal sales from early-stage activities, its substantial market cap of $2.31B reflects significant market expectations regarding the potential value of its lead programs, including MZE829, which targets specific metabolic pathways.
Financial Health
The company reports revenue for the trailing twelve months as N/A, with a net income of $-101,458,000 and an EBITDA of $-131,957,000, figures that highlight a structure dominated by heavy investment costs rather than commercial profit generation. The gap between the reported revenue and the substantial net loss reveals a cost structure typical of pre-revenue biotechnology entities, where expenses for clinical trials, regulatory compliance, and personnel far exceed current sales. Free cash flow stands at $-68,289,752, which indicates that the company is consuming cash reserves to fund operations and development rather than generating surplus liquidity for shareholders. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for entities with negligible sales where these ratios do not provide meaningful operational leverage analysis. Despite the negative earnings, the company holds $383.94M in cash against $24.18M in debt, creating a position where assets significantly outweigh liabilities. The debt-to-equity ratio is 6.37, suggesting a capital structure heavily weighted toward equity financing rather than debt obligations, which mitigates default risk despite the cash burn. Liquidity is further supported by a current ratio of 17.70, indicating a robust ability to meet short-term obligations with existing current assets. However, the return on equity is -52.7% and the return on assets is -27.4%, metrics that mathematically reflect the dilution of shareholder value and asset efficiency due to sustained operating losses rather than management ineptitude in a traditional sense.
Valuation Assessment
Valuation multiples for Maze Therapeutics present unique challenges due to the lack of earnings, with the trailing P/E ratio listed as N/A and the forward P/E ratio at -15.33, implying that the market prices the stock based on non-earnings fundamentals or speculative future cash flows rather than current profitability. The price-to-book ratio is 6.09, indicating that the market values the company at six times its book value, which suggests a significant premium assigned to the potential of its intellectual property and pipeline assets over its tangible net assets. Alternative valuation metrics include a price-to-sales ratio of inf and an EV/EBITDA of -14.79, figures that underscore the inability to value the stock using traditional sales or earnings multiples due to the absence of revenue and negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $53.65 and a 52-week low of $6.71, demonstrating extreme volatility within a wide range. Without a specific current price provided in the source facts to calculate the exact percentage deviation, the wide spread between $53.65 and $6.71 illustrates the high uncertainty inherent in early-stage biotechnology valuation. The beta value is listed as N/A, meaning volatility data relative to the broader market is not available or calculated, which makes standard beta-based risk assessment impossible for this specific ticker.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the fact that the company is not yet in a mature growth phase where consistent year-over-year expansion metrics are applicable or meaningful for analysis. Because the company has not achieved positive earnings, there is no sustainable dividend yield or payout ratio to evaluate, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its remaining resources and cash reserves entirely into research and development activities to advance its clinical programs rather than distributing income to shareholders. This growth and income profile is characteristic of a clinical-stage enterprise where the primary objective is pipeline progression rather than revenue expansion or shareholder yield distribution.